CTCE-0214-DataSheet-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemECTCE-0214Cat.No.:HY-P3612CASNo.:577782-52-6SequenceShortening:KPVSLSYRAPFRFFGGGGLKWIQEYLEKALN-NH2(Lactam:Lys20-Glu24)作⽤靶点:CXCR作⽤通路:GPCR/GProtein;Immunology/Inflammation储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性CTCE-0214⼀种CXCR4(chemokineCXCreceptor4)激动剂，SDF-1α肽类似物。CTCE-0214具有抗炎活性，可⽤于炎症败⾎症和系统性炎症综合征的研究。IC50&TargetSDF-1α-CXCR4体外研究CTCE-0214(0.01-0.1ng/mL;4d)increasestheexpansionofCD34+cellssubsets[3].体内研究CTCE-0214(intravenousinjection;1-25mg/kg;once)treatmentinhibitsLipopolysaccharide-inducedplasmaTNF-αproduction[1].CTCE-0214(intraperitonealinjectionandintravenousinjection;25mg/kg;once)decreasesZymosan-inducedplasmaTNF-αproduction[1].AnimalModel:MaleCD-1miceinjectedwithLipopolysaccharide[1]Dosage:1,10,or25mg/kgAdministration:Intravenousinjection;1,10,or25mg/kg;onceResult:DecreasedLPS-inducedplasmaTNF-αproductioninadosedependentmanorwitha93%reduction.ShowednosignificanteffectonLPS-inducedplasmaIL-6andIL-10production.AnimalModel:Zymosan-inducedperitonitismicemodel[1]1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEDosage:25mg/kgAdministration:Intraperitonealinjectionandintravenousinjection;25mg/kg;onceResult:ShowedasignificantreductioninplasmaTNF-α(53reduction,p<0.05).REFERENCES[1].FanH,etal.BeneficialeffectofaCXCR4agonistinmurinemodelsofsystemicinflammation.Inflammation.2012Feb;35(1):130-7.[2].FaberA,etal.ThemanyfacetsofSDF-1alpha,CXCR4agonistsandantagonistsonhematopoieticprogenitorcells.JBiomedBiotechnol.2007;2007(3):26065.[3].LiK,etal.SmallpeptideanalogueofSDF-1alphasupportssurvivalofcordbloodCD34+cellsinsynergywithothercytokinesandenhancestheirexvivoexpansionandengraftmentintononobesediabetic/severecombinedimmunodeficientmice.StemCells.2006Jan;24(1):55-64.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel